Antibiotic Trial Without Comparator Would Lower R&D Cost, Wyeth Exec Says
Executive Summary
Antibiotic trials without comparator drug arms would lower development costs, Wyeth Antibacterial Research Director Steven Projan, PhD, suggested
You may also be interested in...
Antimicrobial Development Could Benefit From Smaller Clinical Trials – FDA
Upcoming FDA guidances on antimicrobial drug development will address ways to reduce clinical trial size, Center for Drug Evaluation & Research Antimicrobial Drug Development & Resistance Initiatives Lead Medical Officer John Powers, MD, said
Antimicrobial Development Could Benefit From Smaller Clinical Trials – FDA
Upcoming FDA guidances on antimicrobial drug development will address ways to reduce clinical trial size, Center for Drug Evaluation & Research Antimicrobial Drug Development & Resistance Initiatives Lead Medical Officer John Powers, MD, said
Antibiotic Research Stalling In Conversion Of Target Into New Drug
Translating validated targets into clinical candidates is the major hurdle in discovering new antibiotics to combat resistance, Lilly VP-Scientific Affairs Gail Cassell, PhD, suggested in a presentation to FDA's Center for Drug Evaluation & Research Jan. 7
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: